News
and Media
Press Releases and Media
January 30, 2024 | Press Release
Revolo Biotherapeutics Receives Orphan Drug Designation from the U.S. FDA for its First-in-Class Peptide as a Potential Treatment for Eosinophilic Esophagitis
GAITHERSBURG, MD and CAMBRIDGE, UK, January 30, 2024 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ‘1104, a first-in-class […]
November 7, 2023 | Press Release
Revolo Biotherapeutics Presents New Data on ‘1805 at the American College of Rheumatology Convergence 2023 Annual Conference
– New preclinical data further elucidate ‘1805’s mechanism of action in rheumatoid arthritis (RA) – NEW ORLEANS and CAMBRIDGE, UK, November 7, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that new preclinical […]
October 25, 2023 | Press Release
Revolo Biotherapeutics Announces Data from Study of ‘1104 in Atopic Adults
– Treatment with ‘1104 demonstrated a rapid reduction in intradermal allergic inflammation –– Treatment with ‘1104 induced sustained activation of T regulatory and B regulatory cells, providing additional clinical validation of its mechanism of action – NEW ORLEANS and CAMBRIDGE, UK, October 25, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that […]